Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/22/2026

1. MONC:IM
2. PSKY
3. MONRY
4. PTON
5. NYXH
6. TDY
7. PNR
8. ACN
9. ONON
10. IAUX

Go back to Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
Regeneron (NASDAQ: REGN) Delayed: 798.17 --0 (-0%)
Previous Close $798.17    52 Week High $592.36 
Open $798.17    52 Week Low $325.35 
Day High $798.17    P/E 209.49 
Day Low $798.17    EPS $3.81 
Volume 216       

SANOFI (NASDAQ: SNY) Delayed: 42.50 --0 (-0%)
Previous Close $42.50    52 Week High $44.76 
Open $42.50    52 Week Low $36.81 
Day High $42.50    P/E N/A 
Day Low $42.50    EPS $0.00 
Volume 5,309